Most Popular
-
1
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
2
S. Korea not to attend Sado mine memorial: foreign ministry
-
3
First snow to fall in Seoul on Wednesday
-
4
Man convicted after binge eating to avoid military service
-
5
Wealthy parents ditch Korean passports to get kids into international school
-
6
Toxins at 622 times legal limit found in kids' clothes from Chinese platforms
-
7
[Weekender] Korea's traditional sauce culture gains global recognition
![[Weekender] Korea's traditional sauce culture gains global recognition](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050153_0.jpg&u=20241123224317)
-
8
BLACKPINK's Rose stays at No. 3 on British Official Singles chart with 'APT.'
-
9
Korea to hold own memorial for forced labor victims, boycotting Japan’s
-
10
Nvidia CEO signals Samsung’s imminent shipment of AI chips
![[Weekender] Korea's traditional sauce culture gains global recognition](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050153_0.jpg&u=20241123224317)
Samsung Biologics seizes over $330m deal with AstraZeneca
By Lim Jeong-yeoPublished : Sept. 22, 2020 - 15:31
Samsung Biologics signed to contract manufacture AstraZeneca‘s biologics drug for its global distribution, the company said Tuesday.
The size of the contract is $330,840,300, open to grow to $529,599,900 if demand grows for AstraZeneca’s product.
This deal seals the letter of intention Samsung Biologics and AstraZeneca forged on June 23. The contract culmination date is tentatively written as the end of 2028.
“This long-term partnership with Samsung Biologics strengthens our manufacturing capabilities, and ensures we are well-positioned to continue to deliver our exciting portfolio of new and established biologics medicines to patients with quality, speed and efficiency,” said Pam Cheng, AstraZeneca‘s global operations head.
Samsung Biologics will produce both the drug substance, meaning the drug itself, and the finished drug product, meaning the version packaged for sales.
It will use its most cutting-edge facility, factory No. 3, for production of the AstraZeneca drug.
AstraZeneca is entering full-fledged cooperative symbiosis with Korean biologics and health care companies.
On July 21, the company also signed with SK Bioscience to have its COVID-19 vaccine contract manufactured through the Korean firm.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
The size of the contract is $330,840,300, open to grow to $529,599,900 if demand grows for AstraZeneca’s product.
This deal seals the letter of intention Samsung Biologics and AstraZeneca forged on June 23. The contract culmination date is tentatively written as the end of 2028.
“This long-term partnership with Samsung Biologics strengthens our manufacturing capabilities, and ensures we are well-positioned to continue to deliver our exciting portfolio of new and established biologics medicines to patients with quality, speed and efficiency,” said Pam Cheng, AstraZeneca‘s global operations head.
Samsung Biologics will produce both the drug substance, meaning the drug itself, and the finished drug product, meaning the version packaged for sales.
It will use its most cutting-edge facility, factory No. 3, for production of the AstraZeneca drug.
AstraZeneca is entering full-fledged cooperative symbiosis with Korean biologics and health care companies.
On July 21, the company also signed with SK Bioscience to have its COVID-19 vaccine contract manufactured through the Korean firm.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
![[More than APT] Residents, architects together design homes](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/11/24/20241124050036_0.jpg&u=)
